Biotech Values

[DewDiligence]

ADXS/PETX data in canine osteosarcoma:

http://finance.yahoo.com/news/survival-results-advaxis-her2-targeted-110500029.html

The study by Nicola Mason, PhD, BVetMed, Associate Professor of Medicine at the University of Pennsylvania School of Veterinary Medicine, evaluated the immunogenicity, safety, and impact of attenuated, recombinant Listeria monocytogenes (Lm) transformed with a HER2/Neu fusion protein (ADXS-HER2) on survival in 18 dogs with surgically treated osteosarcoma.

…18 dogs received either 2x10^8, 5x10^8, 1x10^9 or 3.3x10^9 CFU of ADXS–HER2 post-completion of surgery and adjuvant chemotherapy with 15 dogs showing an induced antigen-specific response within 6 months of immunotherapy administration. Additionally, treatment with ADXS-HER2 reduced the incidence of metastatic disease and prolonged survival relative to a historical control group. The median survival time for the ADXS-HER2 treated dogs was 956 days which was significantly longer than the 423 day median survival time of the historical control group (p=0.014, HR 0.33; 95% CI 0.136-0.802).

If the HR=0.33 outcome had been achieved relative to an actual control arm, it would warrant a very loud bark.

ADXS out-licensed this program to PETX.